Declining testosterone levels are major global health care concern affecting between 10% and 40% of the male population.
Global male life expectancy is also rising. In the last 5 years alone, it has increased at a steady rate of 2.3% from 68.5 to 70.8 years.3
Longer male life expectancy means more years in which men’s T cell count with Testosterone levels are gradually decreasing
For Acesis BioMed, this means that the market for our proprietary ‘first in class’ T inducing peptide is only growing.
It is reported that a multidirectional association exists between low T and obesity, metabolic status and erectile dysfunction in men, thereby presenting additional target market opportunities for Acesis.
3 Life Expectancy by Country and in the World (2021) - Worldometer (worldometers.info) – Population data taken from United Nations Population Division.
An opportunity to treat anywhere between 10% and 40% of the global male population.
4 Global Male Hypogonadism Market Size, Share 2021-2026 to Post a CAGR of Includes Business Research, Key players, Market Growth, Complete Industry Analysis, Revenue, Future Trends 2026 - MarketWatch
For lead product candidate ACE–167
Projected Hypogonadal Patient Target Population - 2027
United States
Canada
Europe
India
